Journal
PHARMACOLOGICAL REPORTS
Volume 73, Issue 2, Pages 405-434Publisher
SPRINGER HEIDELBERG
DOI: 10.1007/s43440-021-00238-y
Keywords
Cancer; JNK; Inflammation; Kinases; Leukemia
Categories
Ask authors/readers for more resources
JNKs, as members of the MAPK family, regulate various physiological processes and their continuous activation is associated with cancer development. JNK1 and JNK2 have opposite functions in different types of cancers, highlighting the importance of specific JNK inhibitors in cancer therapy.
The JNKs are members of mitogen-activated protein kinases (MAPK) which regulate many physiological processes including inflammatory responses, macrophages, cell proliferation, differentiation, survival, and death. It is increasingly clear that the continuous activation of JNKs has a role in cancer development and progression. Therefore, JNKs represent attractive oncogenic targets for cancer therapy using small molecule kinase inhibitors. Studies showed that the two major JNK proteins JNK1 and JNK2 have opposite functions in different types of cancers, which need more specification in the design of JNK inhibitors. Some of ATP- competitive and ATP non-competitive inhibitors have been developed and widely used in vitro, but this type of inhibitors lack selectivity and inhibits phosphorylation of all JNK substrates and may lead to cellular toxicity. In this review, we summarized and discussed the strategies of JNK binding inhibitors and the role of JNK signaling in the pathogenesis of different solid and hematological malignancies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available